After failure of first-line VEGFR-TKIs sunitinib or sorafenib in aRCC, look to


AFINITOR® (everolimus) Tablets is indicated for the treatment of adults with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.

learn more
learn more
learn more


learn more

Important Safety Information

  • AFINITOR is contraindicated in patients with hypersensitivity to everolimus, other rapamycin derivatives, or any excipients
  • There have been reports of noninfectious pneumonitis, infections, and renal failure (including acute renal failure) in patients taking AFINITOR, some with fatal outcomes
  • Patients taking concomitant angiotensin-converting enzyme (ACE) inhibitor therapy may be at increased risk for angioedema
  • Oral ulceration is the most frequently occurring adverse event and occurred in 44% to 78% of AFINITOR-treated patients across the clinical trial experience. Most of these events were grade 1/2. Grade 3/4 stomatitis was reported in 4% to 9% of patients
  • Exercise caution with the use of AFINITOR in the perisurgical period, as everolimus delays wound healing and increases the occurrence of wound-related complications
  • Elevations of serum creatinine, proteinuria, glucose, lipids, and triglycerides, and reductions of hemoglobin, lymphocytes, neutrophils, and platelets have also been reported; monitoring of laboratory tests is recommended
  • The use of live vaccines and close contact with those who have received live vaccines should be avoided
  • AFINITOR can cause fetal harm when administered to a pregnant woman

Please see additional Important Safety Information.

Please see full Prescribing Information for AFINITOR.

Abbreviations: aRCC, advanced renal cell carcinoma; PFS, progression-free survival; VEGFR-TKI, vascular endothelial growth factor receptor-tyrosine kinase inhibitor.


Important Safety Information

AFINITOR is contraindicated in patients with hypersensitivity to everolimus, to other rapamycin derivatives, or to any of the excipients.

Noninfectious Pneumonitis:


Angioedema With Concomitant Use of Angiotensin-Converting Enzyme (ACE) Inhibitors:

Oral Ulceration:

Renal Failure:

Impaired Wound Healing:

Laboratory Tests and Monitoring:

Drug-Drug Interactions:

Hepatic Impairment:


Embryo-Fetal Toxicity:

Adverse Reactions:

Laboratory Abnormalities:

Please see full Prescribing Information for AFINITOR.

References: 1. AFINITOR [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2015. 2. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma. Cancer, 2010;116:4256-4265. 3. Yuan R, Kay A, Berg W, Lebwohl D, Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol. 2009;2:45.